Literature DB >> 33469743

Concomitant Use of Levothyroxine and Proton Pump Inhibitors in Patients with Primary Hypothyroidism: a Systematic Review.

Yuli Guzman-Prado1, Roberto Vita2, Ondrej Samson3.   

Abstract

BACKGROUND: The aim of this study was to assess the effect of concomitant use of levothyroxine (LT4) and proton pump inhibitors (PPIs) on thyroid-stimulating hormone (TSH) levels in patients with primary hypothyroidism.
METHODS: A systematic review of interventional and observational studies that compared the TSH levels before and after concomitant use of LT4 and PPI was performed. Articles published in English up to September 1, 2019, were included. PubMed, EMBASE, and Cochrane Library databases. Gray literature was also searched in repositories, websites OpenGrey and Google Scholar, and abstracts of major international congresses. Study quality was assessed with the Newcastle-Ottawa quality assessment scale for observational studies and the Risk Of Bias In Non-randomized Studies - of Interventions (ROBINS-I) tool was used.
RESULTS: Five thousand twelve discrete articles were identified. Following assessment and application of eligibility criteria, seven studies were included. There was a considerable heterogeneity among the included studies in design, sample size, inclusion and exclusion criteria, treatment regimen, and baseline demographics. Each of the included studies showed an increase in TSH levels following LT4 and PPI consumption, and in the majority of these, the increase was statistically significant. DISCUSSION: The concomitant use of LT4 and PPI showed a significant increase in TSH concentration. However, given the small number of studies, further research is needed to clarify the interfering role of PPI on LT4 intestinal absorption. PROSPERO REGISTRATION NUMBER: CRD42020047084.

Entities:  

Keywords:  drug interaction; hypothyroidism; levothyroxine

Mesh:

Substances:

Year:  2021        PMID: 33469743      PMCID: PMC8175524          DOI: 10.1007/s11606-020-06403-y

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   6.473


  46 in total

1.  Grading quality of evidence and strength of recommendations.

Authors:  David Atkins; Dana Best; Peter A Briss; Martin Eccles; Yngve Falck-Ytter; Signe Flottorp; Gordon H Guyatt; Robin T Harbour; Margaret C Haugh; David Henry; Suzanne Hill; Roman Jaeschke; Gillian Leng; Alessandro Liberati; Nicola Magrini; James Mason; Philippa Middleton; Jacek Mrukowicz; Dianne O'Connell; Andrew D Oxman; Bob Phillips; Holger J Schünemann; Tessa Tan-Torres Edejer; Helena Varonen; Gunn E Vist; John W Williams; Stephanie Zaza
Journal:  BMJ       Date:  2004-06-19

2.  Undertreated hypothyroidism due to calcium or iron supplementation corrected by oral liquid levothyroxine.

Authors:  Salvatore Benvenga; Flavia Di Bari; Roberto Vita
Journal:  Endocrine       Date:  2017-02-03       Impact factor: 3.633

Review 3.  Consequences of dysthyroidism on the digestive tract and viscera.

Authors:  Ronald Daher; Thierry Yazbeck; Joe Bou Jaoude; Bassam Abboud
Journal:  World J Gastroenterol       Date:  2009-06-21       Impact factor: 5.742

Review 4.  The thyroid and the gut.

Authors:  Ellen C Ebert
Journal:  J Clin Gastroenterol       Date:  2010-07       Impact factor: 3.062

5.  The impact of proton pump inhibitors on levothyroxine absorption: The good, the bad and the ugly.

Authors:  Yuli Guzman-Prado; Roberto Vita; Ondrej Samson
Journal:  Eur J Intern Med       Date:  2020-02-21       Impact factor: 4.487

6.  Drugs that interact with levothyroxine: an observational study from the Thyroid Epidemiology, Audit and Research Study (TEARS).

Authors:  Savannah A Irving; Thenmalar Vadiveloo; Graham P Leese
Journal:  Clin Endocrinol (Oxf)       Date:  2014-08-14       Impact factor: 3.478

7.  A novel formulation of L-thyroxine (L-T4) reduces the problem of L-T4 malabsorption by coffee observed with traditional tablet formulations.

Authors:  Roberto Vita; Giovanna Saraceno; Francesco Trimarchi; Salvatore Benvenga
Journal:  Endocrine       Date:  2012-08-30       Impact factor: 3.633

8.  ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.

Authors:  Jonathan Ac Sterne; Miguel A Hernán; Barnaby C Reeves; Jelena Savović; Nancy D Berkman; Meera Viswanathan; David Henry; Douglas G Altman; Mohammed T Ansari; Isabelle Boutron; James R Carpenter; An-Wen Chan; Rachel Churchill; Jonathan J Deeks; Asbjørn Hróbjartsson; Jamie Kirkham; Peter Jüni; Yoon K Loke; Theresa D Pigott; Craig R Ramsay; Deborah Regidor; Hannah R Rothstein; Lakhbir Sandhu; Pasqualina L Santaguida; Holger J Schünemann; Beverly Shea; Ian Shrier; Peter Tugwell; Lucy Turner; Jeffrey C Valentine; Hugh Waddington; Elizabeth Waters; George A Wells; Penny F Whiting; Julian Pt Higgins
Journal:  BMJ       Date:  2016-10-12

9.  Levothyroxine Therapy: Changes of TSH Levels by Switching Patients from Tablet to Liquid Formulation. A Systematic Review and Meta-Analysis.

Authors:  Camilla Virili; Luca Giovanella; Poupak Fallahi; Alessandro Antonelli; Maria Giulia Santaguida; Marco Centanni; Pierpaolo Trimboli
Journal:  Front Endocrinol (Lausanne)       Date:  2018-01-26       Impact factor: 5.555

10.  Thyroxine Treatment With Softgel Capsule Formulation: Usefulness in Hypothyroid Patients Without Malabsorption.

Authors:  Pierpaolo Trimboli; Camilla Virili; Marco Centanni; Luca Giovanella
Journal:  Front Endocrinol (Lausanne)       Date:  2018-03-21       Impact factor: 5.555

View more
  2 in total

1.  Liquid levothyroxine sodium therapy improves pharmacologic thyroid-stimulating hormone homeostasis in patients with reduced efficacy for tablet levothyroxine sodium after sleeve gastrectomy. A case report.

Authors:  Luigi Schiavo; Annalisa Giosuè; Viviana Izzo; Fabrizio Dal Piaz; Amelia Filippelli; Vincenzo Pilone
Journal:  Obes Surg       Date:  2021-06-18       Impact factor: 4.129

2.  Daily requirement of softgel thyroxine is independent from gastric juice pH.

Authors:  Camilla Virili; Silvia Capriello; Ilaria Stramazzo; Nunzia Brusca; Maria Giulia Santaguida; Lucilla Gargano; Maria Flavia Bagaglini; Giovanni Bruno; Carola Severi; Marco Centanni
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-26       Impact factor: 6.055

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.